Evidence map›Paper›PMID 42072479›Full record

ArticleBiomedicines2026

DYRK1B Inhibition by AZ191 Sensitizes High-Grade Serous Ovarian Cancer to Niraparib Through Promoting Apoptosis and Ferroptosis.

Yu Gao, Yuanyuan Cao, Junyao Liu, Fang Tong, Xianlin Liu, Jiahui Wang, Peixuan Liu, Yanting Xu, Lu Feng, Pengxin Zhang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yu GaoDepartment: of Oncology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China.
Yuanyuan CaoDepartment of Obstetrics & Gynecology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China.
Junyao LiuDepartment of Obstetrics & Gynecology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China.
Fang TongDepartment of Obstetrics & Gynecology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China.
Xianlin LiuDepartment of Obstetrics & Gynecology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China.ORCID 0009-0000-7785-3034
Jiahui WangDepartment of Obstetrics & Gynecology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China.
Peixuan LiuDepartment of Obstetrics & Gynecology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China.
Yanting XuDepartment of Obstetrics & Gynecology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China.
Lu FengDepartment of Pathology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China.
Pengxin ZhangDepartment of Pathology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China.
Jingchun GaoDepartment of Obstetrics & Gynecology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China.
Jiwei LiuDepartment: of Oncology, First Affiliated Hospital, Dalian Medical University, Dalian 116011, China.

Funding

National Natural Science Foundation of China 81172457National Natural Science Foundation of China 82172793
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

apoptosisDYRK1Bferroptosisovarian cancerPARP inhibitor

Identifiers

PMID42072479
PMCPMC13114077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.